A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2018
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms IGUANA
- Sponsors Galapagos NV
- 19 Dec 2018 Planned number of patients changed from 180 to 240.
- 19 Jul 2018 According to a MorphoSys media release, MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner,Upon the signing of the agreement, all future research, development, manufacturing and commercialization costs for MOR106 will be borne by Novartis.
- 01 May 2018 Status changed from planning to recruiting, according to a MorphoSys media release.